Specialty pharmaceutical company Shire has put up the price for its leading hyperactivity drug Adderall XR by 20 percent, exceeding analyst expectations and prompting Citigroup to upgrade the company's stock.
The price increase outstrips the 7 percent increase for Shire's newer hyperactivity medicine Vyvanse and is expected to encourage switching to the new product.
More
Hmm.
No comments:
Post a Comment